rs747344293
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000527.5(LDLR):c.2478del(p.Val827SerfsTer102) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,848 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 31)
Exomes 𝑓: 6.8e-7 ( 0 hom. )
Consequence
LDLR
NM_000527.5 frameshift
NM_000527.5 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.0920
Genes affected
LDLR (HGNC:6547): (low density lipoprotein receptor) The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. The encoded protein is normally bound at the cell membrane, where it binds low density lipoprotein/cholesterol and is taken into the cell. Lysosomes release the cholesterol, which is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
?
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
?
Very rare variant in population databases, with high coverage;
PP5
?
Variant 19-11129597-AC-A is Pathogenic according to our data. Variant chr19-11129597-AC-A is described in ClinVar as [Pathogenic]. Clinvar id is 252342.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr19-11129597-AC-A is described in Lovd as [Pathogenic]. Variant chr19-11129597-AC-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.2478del | p.Val827SerfsTer102 | frameshift_variant | 17/18 | ENST00000558518.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
LDLR | ENST00000558518.6 | c.2478del | p.Val827SerfsTer102 | frameshift_variant | 17/18 | 1 | NM_000527.5 | P3 |
Frequencies
GnomAD3 genomes ? Cov.: 31
GnomAD3 genomes
?
Cov.:
31
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461848Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 727222
GnomAD4 exome
AF:
AC:
1
AN:
1461848
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
727222
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? Cov.: 31
GnomAD4 genome
?
Cov.:
31
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Robarts Research Institute, Western University | Jan 02, 2018 | - - |
Pathogenic, criteria provided, single submitter | literature only | LDLR-LOVD, British Heart Foundation | Mar 25, 2016 | - - |
Pathogenic, criteria provided, single submitter | curation;literature only | Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge | Mar 01, 2016 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 23, 2018 | The c.2478delC pathogenic variant in the LDLR gene was paternally inherited in a Chinese child with severe familial hypercholesterolemia and a second maternally inherited variant in the LDLR gene; of note, the heterozygous father was reported to have elevated cholesterol (Sun et al., 1994). This variant causes a shift in reading frame starting at codon valine (Val) 827, changing it to a serine (Ser), and creating a premature stop codon at position 102 of the new reading frame, denoted p.Val827SerfsX102. This pathogenic variant is located in the penultimate exon and is predicted to result in an abnormal protein product with the last 34 amino acid residues replaced by 101 incorrect amino acid residues. Functional studies show that the c.2478delC variant results in either no detectable LDLR protein, or low levels of LDLR protein that is unable to bind the LDL ligand (Sun et al., 1994). Other frameshift variants in the LDLR gene have been reported in Human Gene Mutation Database in association with FH (Stenson et al., 2014), including a different downstream frameshift variant (c.2509delC) predicted to use the same termination codon as the c.2478delC variant. Furthermore, the c.2478delC variant has not been observed in large population cohorts (Lek et al., 2016). - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 12, 2023 | The c.2478delC (p.V827Sfs*102) alteration, located in exon 17 (coding exon 17) of the LDLR gene, consists of a deletion of one nucleotide at position 2478, causing a translational frameshift with a predicted alternate stop codon after 102 amino acids. This alteration occurs at the 3' terminus of theLDLR gene, is not expected to trigger nonsense-mediated mRNAdecay and results in the elongation of the protein by 67 amino acids. This frameshift impacts the last 34 amino acids(~4%) of the native protein. However, frameshifts are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration, referred to as a 1-bp deletion in codon 805, was reported in a family with familial hypercholesterolemia and in vitro studies suggested that it would affect LDLR protein expression or stability (Sun, 1994). Based on the available evidence, this alteration is classified as pathogenic. - |
Familial hypercholesterolemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Nov 04, 2022 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the LDLR protein in which other variant(s) (p.Ser849*) have been determined to be pathogenic (PMID: 2088165, 11933210, 22509010, 26892515). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Experimental studies have shown that this premature translational stop signal affects LDLR function (PMID: 7903864). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains an entry for this variant (Variation ID: 252342). This premature translational stop signal has been observed in individual(s) with hypercholesterolemia (PMID: 7903864). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Val827Serfs*102) in the LDLR gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 34 amino acid(s) of the LDLR protein. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at